Thomas D Scanlan

US Patent:

7645885, Jan 12, 2010

Filed:

Aug 28, 2006

Appl. No.:

11/467908

Inventors:

Thomas S. Scanlan - Portland OR, US
Dmitry V. Kadnikov - Dekalb IL, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C07D 261/20
C07D 231/54
A61K 31/416
A61K 31/42

US Classification:

5483591, 548241, 514379, 514406

Abstract:

The invention provides non-steroidal ligands for the androgen receptor, methods for making non-steroidal ligands of the androgen receptor, compositions of non-steroidal ligands of the androgen receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the androgen receptor for treating or preventing diseases (e. g. , prostate cancer) associated with androgen binding to the androgen receptor.

US Patent:

7947726, May 24, 2011

Filed:

Feb 3, 2009

Appl. No.:

12/365106

Inventors:

Thomas S. Scanlan - Portland OR, US
Nilesh Shah - San Francisco CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/416
C07D 231/54

US Classification:

514406, 5483561, 5483581, 5483591, 514410, 514411

Abstract:

The invention provides non-steroidal ligands for the glucocorticoid receptor, methods for making non-steroidal ligands of the glucocorticoid receptor, compositions of non-steroidal ligands of the glucocorticoid receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the glucocorticoid receptor for treating or preventing diseases (e. g. , obesity, diabetes, depression, neurodegeneration or an inflammatory disease) associated with glucocorticoid binding to the glucocorticoid receptor.

US Patent:

8236987, Aug 7, 2012

Filed:

Nov 9, 2007

Appl. No.:

11/938129

Inventors:

Thomas S. Scanlan - Portland OR, US
Toru Iijima - Saitama, JP

Assignee:

The Regents of the University of California - Oakland CA
Oregon Health & Science University - Portland OR

International Classification:

C07C 233/00

US Classification:

564207, 564 84, 564 95, 564171, 564192, 564204, 514627

Abstract:

The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions.

US Patent:

20110218225, Sep 8, 2011

Filed:

May 11, 2011

Appl. No.:

13/105349

Inventors:

Thomas S. Scanlan - Portland OR, US
Nilesh Shah - San Francisco CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/416
C07D 231/54
A61P 3/04
A61P 3/10
A61P 25/22
A61P 25/24
A61P 25/00
A61P 29/00

US Classification:

514406, 5483591

Abstract:

The invention provides non-steroidal ligands for the glucocorticoid receptor, methods for making non-steroidal ligands of the glucocorticoid receptor, compositions of non-steroidal ligands of the glucocorticoid receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the glucocorticoid receptor for treating or preventing diseases (e.g., obesity, diabetes, depression, neurodegeneration or an inflammatory disease) associated with glucocorticoid binding to the glucocorticoid receptor.

US Patent:

20140018426, Jan 16, 2014

Filed:

Sep 12, 2013

Appl. No.:

14/025422

Inventors:

Thomas S. Scanlan - Portland OR, US

Assignee:

T*Amine, LLC - Salt Lake City UT

International Classification:

A61K 31/198

US Classification:

514567

Abstract:

Food or beverage compositions fortified with thyronines and/or thyronamines, processes for increasing T2, T1AM, and/or T0AM in a subject by administering a food or beverage composition that is fortified with at least one thyronine and/or thyronamine compound, and processes for promoting a healthy state by administering a food or beverage composition to a subject that is fortified with at least one thyronine and/or thyronamine compound. Increased levels of T2, T1AM, and/or T0AM in a subject can be associated with at least one of healthy cholesterol levels, healthy triglyceride levels, healthy blood sugar levels, cardiovascular health, healthy sleep patterns, healthy mood, healthy skin, healthy nails, or healthy endocrine function and/or a number of other markers of associated with general health and well-being.

US Patent:

20210002208, Jan 7, 2021

Filed:

Feb 13, 2019

Appl. No.:

16/969793

Inventors:

- Portland OR, US
Thomas SCANLAN - Portland OR, US

Assignee:

OREGON HEALTH & SCIENCE UNIVERSITY - Portland OR

International Classification:

C07C 233/40
C07C 233/11
C07C 233/22
C07C 233/13

Abstract:

Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.

US Patent:

20160244418, Aug 25, 2016

Filed:

Feb 19, 2016

Appl. No.:

15/048672

Inventors:

Thomas S. Scanlan - Portland OR, US
Andrew Placzek - Portland OR, US
Tapasree Banerji - West Linn OR, US
Sky Ferrara - Portland OR, US
James Matthew Meinig - Portland OR, US

Assignee:

OREGON HEALTH & SCIENCE UNIVERSITY - PORTLAND OR

International Classification:

C07D 295/088
C07C 229/08
C07C 237/12
C07D 205/04
C07D 233/64
C07D 207/08
C07D 211/44
C07D 211/42
C07D 211/22
C07C 69/708
C07D 309/10

Abstract:

Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.